Institution
Tehran University of Medical Sciences
Education•Tehran, Iran•
About: Tehran University of Medical Sciences is a education organization based out in Tehran, Iran. It is known for research contribution in the topics: Population & Medicine. The organization has 35661 authors who have published 57234 publications receiving 878523 citations. The organization is also known as: TUMS.
Topics: Population, Medicine, Cancer, Randomized controlled trial, Health care
Papers published on a yearly basis
Papers
More filters
••
TL;DR: In this article, a case of sinonasal mucormycosis in a 44-year-old woman with hyperglycaemia secondary to poorly controlled diabetes following dexamethasone therapy on a background of influenza pneumonia was reported.
Abstract: Acute respiratory distress syndrome is a common complication of severe viral pneumonia, such as influenza and COVID-19, that requires critical care including ventilatory support, use of corticosteroids and other adjunctive therapies to arrest the attendant massive airways inflammation. Although recommended for the treatment of viral pneumonia, steroid therapy appears to be a double-edged sword, predisposing patients to secondary bacterial and invasive fungal infections (IFIs) whereby impacting morbidity and mortality. Mucormycosis is a fungal emergency with a highly aggressive tendency for contiguous spread, associated with a poor prognosis if not promptly diagnosed and managed. Classically, uncontrolled diabetes mellitus (DM) and other immunosuppressive conditions including corticosteroid therapy are known risk factors for mucormycosis. Upon the background lung pathology, immune dysfunction and corticosteroid therapy, patients with severe viral pneumonia are likely to develop IFIs like aspergillosis and mucormycosis. Notably, the combination of steroid therapy and DM can augment immunosuppression and hyperglycaemia, increasing the risk of mucormycosis in a susceptible individual. Here, we report a case of sinonasal mucormycosis in a 44-year-old woman with hyperglycaemia secondary to poorly controlled diabetes following dexamethasone therapy on a background of influenza pneumonia and review 15 available literatures on reported cases of influenza and COVID-19 associated mucormycosis.
127 citations
••
Paris Descartes University1, Rockefeller University2, French Institute of Health and Medical Research3, Pasteur Institute4, Centre national de la recherche scientifique5, Garvan Institute of Medical Research6, Singapore General Hospital7, Karolinska University Hospital8, University of Vermont9, University of New South Wales10, Qatar Airways11, Université de Montréal12, University of Ottawa13, Memorial Sloan Kettering Cancer Center14, University of Chile15, Pontifical Catholic University of Chile16, Icahn School of Medicine at Mount Sinai17, University of La Frontera18, Federal University of São Paulo19, University of São Paulo20, Bilkent University21, University of Erlangen-Nuremberg22, Tehran University of Medical Sciences23, San Sebastián University24, Seattle Children's Research Institute25, Beijing Genomics Institute26
TL;DR: Homozygosity for the catalytically inactive P1104A missense variant of the TYK2 Janus kinase selectively disrupts the induction of IFN-γ by IL-23 and is a common monogenic etiology of tuberculosis.
Abstract: Inherited IL-12Rβ1 and TYK2 deficiencies impair both IL-12- and IL-23-dependent IFN-γ immunity and are rare monogenic causes of tuberculosis, each found in less than 1/600,000 individuals. We show that homozygosity for the common TYK2 P1104A allele, which is found in about 1/600 Europeans and between 1/1000 and 1/10,000 individuals in regions other than East Asia, is more frequent in a cohort of patients with tuberculosis from endemic areas than in ethnicity-adjusted controls (P = 8.37 × 10-8; odds ratio, 89.31; 95% CI, 14.7 to 1725). Moreover, the frequency of P1104A in Europeans has decreased, from about 9% to 4.2%, over the past 4000 years, consistent with purging of this variant by endemic tuberculosis. Surprisingly, we also show that TYK2 P1104A impairs cellular responses to IL-23, but not to IFN-α, IL-10, or even IL-12, which, like IL-23, induces IFN-γ via activation of TYK2 and JAK2. Moreover, TYK2 P1104A is properly docked on cytokine receptors and can be phosphorylated by the proximal JAK, but lacks catalytic activity. Last, we show that the catalytic activity of TYK2 is essential for IL-23, but not IL-12, responses in cells expressing wild-type JAK2. In contrast, the catalytic activity of JAK2 is redundant for both IL-12 and IL-23 responses, because the catalytically inactive P1057A JAK2, which is also docked and phosphorylated, rescues signaling in cells expressing wild-type TYK2. In conclusion, homozygosity for the catalytically inactive P1104A missense variant of TYK2 selectively disrupts the induction of IFN-γ by IL-23 and is a common monogenic etiology of tuberculosis.
127 citations
••
TL;DR: The SAR of this series indicates that both the structure of the benzyl unit and the S or SO(2) linker dramatically impact antibacterial activity.
127 citations
••
TL;DR: Omega-3 fatty acids may be an efficient neuroprotective agent for prophylaxis against PIPN and patients with breast cancer have a longer disease free survival rate with the aid of therapeutical agents.
Abstract: Axonal sensory peripheral neuropathy is the major dose-limiting side effect of paclitaxel.Omega-3 fatty acids have beneficial effects on neurological disorders from their effects on neurons cells and inhibition of the formation of proinflammatory cytokines involved in peripheral neuropathy. This study was a randomized double blind placebo controlled trial to investigate the efficacy of omega-3 fatty acids in reducing incidence and severity of paclitaxel-induced peripheral neuropathy (PIPN). Eligible patients with breast cancer randomly assigned to take omega-3 fatty acid pearls, 640 mg t.i.d during chemotherapy with paclitaxel and one month after the end of the treatment or placebo. Clinical and electrophysiological studies were performed before the onset of chemotherapy and one month after cessation of therapy to evaluate PIPN based on "reduced Total Neuropathy Score". Twenty one patients (70%) of the group taking omega-3 fatty acid supplement (n = 30) did not develop PN while it was 40.7%( 11 patients) in the placebo group(n = 27). A significant difference was seen in PN incidence (OR = 0.3, .95% CI = (0.10-0.88), p = 0.029). There was a non-significant trend for differences of PIPN severity between the two study groups but the frequencies of PN in all scoring categories were higher in the placebo group (0.95% CI = (−2.06 -0.02), p = 0.054). Omega-3 fatty acids may be an efficient neuroprotective agent for prophylaxis against PIPN. Patients with breast cancer have a longer disease free survival rate with the aid of therapeutical agents. Finding a way to solve the disabling effects of PIPN would significantly improve the patients’ quality of life. This trial was registered at ClinicalTrials.gov (NCT01049295)
127 citations
•
TL;DR: Animal studies support the beneficial effects of n-3 fatty acids on bone health and osteoporosis; however, the dissimilar lipid metabolism in human and animals, the various study designs, and controversies over the human study outcomes make it difficult to draw a definite conclusion.
Abstract: Osteoporosis, especially in postmenopausal women, delineates a major health and economic problem in the world. Regarding the pathogenesis of osteoporosis and the interaction between various cells and mediators, many studies have been conducted to evaluate the benefit of different therapeutic options. Over the past several years evidence has been growing on the effects of dietary fatty acids on bone health. The objective of this paper was to provide a review of the current knowledge of dietary fatty acids and osteoporosis. Medline/Index Medicus and EMBASE/Excerpta Medica were searched for relevant papers regarding the effects of n-3 fatty acids on osteoporosis between 1963 and 2007 using the key words: osteoporosis, bone health, n-3 fatty acids, and PUFA. Bone mineral density and bone markers have been used in several animal studies to evaluate the beneficial effect of n-3 fatty acids on bone health and the prevention of osteoporosis. Generally, animal studies support the beneficial effects of n-3 fatty acids on bone health and osteoporosis; however, the dissimilar lipid metabolism in human and animals, the various study designs, and controversies over the human study outcomes make it difficult to draw a definite conclusion. The authors believe that conclusive findings in humans are still lacking in this area and it needs to be further investigated.
127 citations
Authors
Showing all 35946 results
Name | H-index | Papers | Citations |
---|---|---|---|
Graeme J. Hankey | 137 | 844 | 143373 |
Paul D.P. Pharoah | 130 | 794 | 71338 |
Jerome Ritz | 120 | 644 | 47987 |
Reza Malekzadeh | 118 | 900 | 139272 |
Robert N. Weinreb | 117 | 1124 | 59101 |
Javad Parvizi | 111 | 969 | 51075 |
Omid C. Farokhzad | 110 | 329 | 64226 |
Ali Mohammadi | 106 | 1149 | 54596 |
Alexander R. Vaccaro | 102 | 1179 | 39346 |
John R. Speakman | 95 | 667 | 34484 |
Philip J. Devereaux | 94 | 443 | 110428 |
Rafael Lozano | 94 | 265 | 126513 |
Mohammad Abdollahi | 90 | 1045 | 35531 |
Ingmar Skoog | 89 | 458 | 28998 |
Morteza Mahmoudi | 83 | 334 | 26229 |